retatrutide liver disease Since January 2026, there have been six cases of acute toxicity associated with unapproved peptide products labelled in Australia. These toxic effects may be linked to a contaminant in the retatrutide nonalcoholic fatty liver disease

Retatrutide Peptide Research Retatrutide is a synthetic peptide that has gained increasing interest in scientific research involving metabolic signaling pathways and receptor activity

Key findings: 12 mg dose: Average weight loss of 24.2% of body weight (approximately 58 lbs for a 240 lb individual) 8 mg dose: Average weight loss of 22.8% 4 mg dose: Average weight loss of 17.0% Placebo: Average weight loss of 2.1% Over 90% of participants receiving the 8 mg or 12 mg dose lost at least 10% of body weight Over 75% of participants at the highest dose lost at least 20% of body weight Significant improvements in waist circumference, blood pressure, and lipid profiles were observed across dose groups Phase 2 Trial in Type 2 Diabetes A separate phase 2 trial evaluated retatrutide in adults with type 2 diabetes and obesity (Rosenstock et al., Lancet , 2023)

Why is retatrutide called a triple agonist

Up-to-date amenities and facilities that are patient-oriented

Several factors influence IV therapy pricing and understanding them helps explain why prices vary so widely